References
- Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388:2796–2810.
- Babjuk M, Bohle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447–461.
- Regionalt cancercentrum i samverkan. Nationellt vårdprogram: Vårdprogram för urinblåsa, njurbäcken, urinledare och urinrör [Cancer in the urinary bladder, kidney pelvis, ureter and urethra, National guideline]. 2015 [cited. Report available at http://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase–och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf
- Chang S, Boorjian S. Diagnosis and treatment of non- muscle invasive bladder cancer:AUA/SUO guideline: American Urological Association; 2016. Available from: https://www.auanet.org/guidelines/non-muscle-invasive-bladder-cancer
- Malmström PU, Agrawal S, Blackberg M, et al. Non-muscle-invasive bladder cancer: a vision for the future. Scand J Urol. 2017;51:87–94.
- Patschan O, Holmäng S, Hosseini A, et al. Use of bacillus Calmette-Guerin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scand J Urol. 2015;49:127–132.
- Vahr S, Love-Retinger N, Jensen BT, et al. EAUN Guidelines. Intravesical instillation with mitomycin C or bacillus Calmette-Guérin in non-muscle invasive bladder cancer http://nurses.uroweb.org/nurses/guidelines/: EAUN; 2015.
- Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129.
- FASS.se För Vårdpersonal Stockholm Läkemedelsindustriföreningen (LIF) [Pharmacy and drug information, Sweden]; 2015. Available from: http://www.fass.se
- Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2000;31: S86–S90.
- Lamm DL, Thor DE, Harris SC, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124:38–40.
- Wei L, Li Q, Liang H, et al. The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemother (Florence, Italy). 2014;26:165–168.
- Singer S, Ziegler C, Schwalenberg T, et al. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21:1383–1393.
- Mack D, Frick J. Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer . Br J Urol. 1996;78:369–371.
- Yoshimura K, Utsunomiya N, Ichioka K, et al. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology 2005;65:290–294.
- Schmidt S, Frances A, Lorente Garin JA, et al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015;33:19.e7–15.
- Bohle A, Balck F, von Weitersheim J, et al. The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol. 1996;155:1221–1226.
- Mogensen K, Christensen KB, Vrang ML, et al. Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol. 2016;50:170-174.
- Babjuk M, Burger M, Zigeuner R, et al. Gudelines Non-muscle-Invasive Bladder Cancer (TaT1 and CIS): European Association of Urology; 2013 [cited 2013 13 maj]. Available from: http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf
- Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study . Eur Urol. 2010;57:25–31.
- Hemdan T, Johansson R, Jahnson S, et al. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer. J Urol. 2014;191:1244–1249.
- Jahnson S, Wiklund F, Duchek M, et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol. 2005;39:206–210.
- Steineck G, Bergmark K, Henningsohn L, et al. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol (Stockholm, Sweden). 2002;41:244–252.
- Jönsson P, Wohlin C. Benchmarking k-nearest neighbour imputation with homogeneous Likert data. Empir Software Eng. 2007;11: 463–489.
- Lundholm C, Norlen BJ, Ekman P, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1996;156:372–376.
- BCG -Medac Patientinformation. 2017. Located at: http://www.medac.se/halsosjukvard/wp-content/uploads/2015/06/BCG-pb-SE_jan2017-1.pdf
- BCG-Medac: FASS Allmänhet; 2017 Available from: http://www.fass.se/LIF/product?userType=2&nplId=20020419000099
- OncoTice Fass allmänhet2017. Available from: http://www.fass.se/LIF/product?docType=7&specId=&userType=&nplId=19920703000030&#side-effects